🟢 ARKG is trading 3.1% up today on Eli Lilly’s $3.8B acquisition and biotech optimism

ARKG is trading at $39.45 (≈+3.1%) as Eli Lilly’s $3.8B acquisition of AtaiBeckley fuels momentum in the genomics and advanced therapeutics space.

• Eli Lilly’s acquisition expands its portfolio into psychedelic depression treatments, driving renewed investor interest in innovative biotech and genomic pipelines.
• Broader healthcare sentiment is further bolstered by the FDA’s traditional approval of Lilly’s cancer drug selpercatinib, reinforcing confidence in the sector's regulatory progress.